Auxilium Pharmaceuticals — Morgan Stanley Healthcare Conference 2014
36 slides from Auxilium Pharmaceuticals's conference presentation, Sep 10, 2014

Slide 1: Morgan Stanley Healthcare Conference Corporate Overview
Morgan Stanley Healthcare Conference Corporate Overview September 10, 2014

Slide 2: Safe Harbor
Safe Harbor We will make various remarks during this presentation that constitute "forward-looking statements" for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995, including statements regarding: the Company's expected financial performance, includin

Slide 3: No Offer or Solicitation
No Offer or Solicitation No Offer or Solicitation This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or

Slide 4: Corporate Overview - Agenda
Corporate Overview - Agenda Corporate Strategy and Business Platform Cost Restructuring Product Portfolio: Growth Opportunities XIAFLEX (Peyronie’s Disease and Dupuytren’s Contracture) STENDRA edex TESTOPEL R&D Pipeline and Franchise Development Label Expansion Opportunities Cellulite Frozen Shoulde

Slide 5: Auxilium Executing Multi-Phase Growth Strategy
Auxilium Executing Multi-Phase Growth Strategy Acquisition of Actient, STENDRA in-licensing Expanded product portfolio and established anchor leadership position in men’s healthcare Grew from 2 to 12 products PHASE ONE: 2013 PHASE THREE: 2015 & Beyond Fully leverage and grow the base business Divers

Slide 6: Auxilium: Cost Restructuring Increases Efficiency
Auxilium: Cost Restructuring Increases Efficiency Corporate restructuring designed to streamline operations, maximize cash flow and drive sustainable earnings growth Focus on leaner operating model and continued importance of effective execution: Expected to reduce annual operating expenses by at le

Slide 7: Auxilium Int'l Corp.: Platform for Growth
Auxilium Int’l Corp.: Platform for Growth Merger with QLT designed to create platform to accelerate Auxilium’s transformation Canadian-domiciled structure creates competitive advantage Anticipated effective tax rate of mid 20% range by 2018 Potential for accelerated reduction through M&A and partner

Slide 8: Auxilium Int'l Corp.: Advantaged Platform
Auxilium Int’l Corp.: Advantaged Platform Value enhancement from the Canadian domicile to existing business Designed to reduce the long-term effective tax rate (ETR) from the high 30% range to the mid 20% range Potential for accelerated reduction in ETR through continued partnering and M&A September

Slide 9: Product Portfolio
Product Portfolio

Slide 10: Diversified Product Portfolio and R&D Pipeline
Diversified Product Portfolio and R&D Pipeline Erectile Dysfunction Low Testosterone Peyronie’s Disease Adhesive Capsulitis Cellulite Orthopedics/ Dermatology PIPELINE TREATMENTS MEN’S HEALTHCARE Additional medications include: Ophthalmology* Impaired Dark Adaptation** PIPELINE TREATMENTS Leber Cong

Slide 11: XIAFLEX: Overall Product Performance
XIAFLEX: Overall Product Performance Strong initial launch momentum in Peyronie’s disease Stable growth traction in Dupuytren’s contracture 2Q 2014: $26.3M XIAFLEX U.S. Revenues by Quarter +75%

Slide 12: XIAFLEX for PD: Focused Launch Strategy
XIAFLEX for PD: Focused Launch Strategy Category Invasive Surgical1 Invasive Non-Surgical1 Non-Invasive No Treatment2 Description / Examples Plication, grafting, prosthesis Verapamil injection Vitamin E, potaba, colchicine Patient Counts 1,500 – 2,000 3,500 – 4,500 ~52,000 ~38,000 Urology Centers ~1

Slide 13: XIAFLEX for PD: Strong Initial Launch Momentum
XIAFLEX for PD: Strong Initial Launch Momentum Auxilium Advantage; All numbers as of August 18 2014 94% Approved 52% Decision Made 48% Currently in Process PD Patients Submitted Through August 18, 2014 4,332 Total Physicians Certified Through August 18, 2014 1,335

Slide 14: XIAFLEX for PD: Strong Initial Launch Momentum
XIAFLEX for PD: Strong Initial Launch Momentum 6,198 Vials Total * Vials shipped to physicians represents in-market demand. Revenues for PD are recognized by Company when sold to wholesalers. Estimates do not include vials shipped to large hospital centers that treat both PD and DC. Historical adjus

Slide 15: XIAFLEX in DC: Stable Growth Traction
XIAFLEX in DC: Stable Growth Traction 7% increase in vial sales over 2Q 2013 Stable XIAFLEX market share 33% YTD through June Increasing awareness & demand for DC procedures Rolling 12-month total procedures: April 2014: 66,324 April 2013: 63,201 4.9 % increase 2011 2012 2013 2014 XIAFLEX in DC: Qua

Slide 16: STENDRA: First ED Drug Approved in Years
STENDRA: First ED Drug Approved in 10 Years Exciting and distinct product profile Rapid – can be taken 30 minutes before sexual activity Able to be taken with food and modest alcohol Designed to be a selective PDE5 inhibitor; low incidence of AEs in clinical trials

Slide 17: STENDRA: Growth in Rx's and Productivity
STENDRA: Growth in Rx’s and Productivity STENDRA Rx Since Launch IMS Health, 2014; based on all data available as of June 30, 2014; * Revenues recognized by Company at time product shipped to wholesalers $6.1 Million in 2Q Revenues* Increasing number of total prescribers: End of Q1: 5,704 End of Q2:

Slide 18: STENDRA: Initial Launch Traction
Weekly STENDRA TRx Share of Oral ED Market STENDRA: Initial Launch Traction IMS Health, 2014; based on all data available as of September 8, 2014 3.6% 1.6% 0.5% Jan Feb Mar Apr May Jun Jul Aug 5.0%

Slide 19: edex: Continued Market Leadership
edex: Continued Market Leadership Market-leading injectable ED treatment Rapid onset; convenient single-dose dual-chamber cartridge Non-oral ED treatments represent ~0.5% of total ED TRx1 2Q 2014 revenues of $7.5 million 50% increase over 2Q 2013 51.8% retail market share as of 2Q 20141 1 IMS Health

Slide 20: TESTOPEL: Growth Opportunity
Only FDA-approved long-acting testosterone pellet available Lasts ~3-4 months 1H 2014 net revenues of $36.2 M 15% price increase on April 1 believed to have driven $12-14 million product buy-in in 1Q 2014 A 2Q impact was expected Additional wholesaler destocking believed to have affected 2Q ex-facto

Slide 21: R&D Pipeline and Franchise Management
R&D Pipeline and Franchise Management

Slide 22: Franchise Management: Label Expansion
Franchise Management: Label Expansion 1 Consumer Impact Research; January 2013 2 Ipsos DC Buying Process, Patient survey Aug-Sept 12, HCP survey Sept-Oct 12, HCP (n= 496, PCP= 126) all specialty samples contain targets and non-targets), DC sufferers n= 177; Brandware 3 Clarity Pharma DC Patient Char

Slide 23: R&D: Cellulite Phase 2a Clinical Trial
R&D: Cellulite Phase 2a Clinical Trial Phase 2a trial results announced in August 2014 Randomized, placebo-controlled study of 150 women in U.S. Three doses of CCH (low (0.06mg), mid (0.48mg) and high (0.84mg) evaluated Mid and high level CCH doses demonstrated statistically significant improvement

Slide 24: R&D: Cellulite Phase 2a Clinical Trial - Subject B
Subject B – High Dose Texture Photography Day 1 Pre-Treatment Day 73 30 Days Following Last Treatment R&D: Cellulite Phase 2a Clinical Trial

Slide 25: R&D: Cellulite Phase 2a Clinical Trial - Subject C
Subject C – High Dose Texture Photography Day 1 Pre-Treatment Day 73 30 Days Following Last Treatment R&D: Cellulite Phase 2a Clinical Trial

Slide 26: R&D: Frozen Shoulder Syndrome
R&D: Frozen Shoulder Syndrome Prolonged, painful capsular collagen thickening; affects 2-5% of adults Full duration of frozen stage (Stage 2) can last from 1 to 3.5 years Causes pain, stiffness and decreased range of motion ~300,000 cases of FSS are diagnosed annually and ~10% are treated with an in

Slide 27: FSS: Phase 2a Results - Forward Flexion
FSS: Phase 2a Results Forward Flexion: Cohort 3 – 0.58 mg / 1 mL 42.9o (41.5%) Overall Improvement 103.4o Baseline 146.3o Post Treatment P<0.05 Comparison to Exercise Cohort

Slide 28: FSS: Phase 2a Results - Shoulder Abduction
FSS: Phase 2a Results Shoulder Abduction: Cohort 3 – 0.58 mg / 1 mL 81.9o Baseline 135.6o Post Treatment 53.7o (65.6%) Overall Improvement P<0.05 Comparison to Exercise Cohort

Slide 29: Strategic Priorities & Upcoming Milestones
Strategic Priorities & Upcoming Milestones

Slide 30: Strategic Priorities & Milestones Moving Forward
Strategic Priorities & Milestones Moving Forward Continue to successfully launch two new products: STENDRA for ED and XIAFLEX for PD Grow TESTOPEL and edex use with urologists Drive XIAFLEX to standard of care in Dupuytren’s Maximize value of current portfolio Successfully advance R&D opportunities
![Slide 31: fa a] = ® 2. <x](https://6ix-events-pro.s3.amazonaws.com/decks/p/0qqvyuo2/31.webp)
Slide 31: fa a] = ® 2. <x
fa a] = ® 2. 2 <x

Slide 32: 2Q 2014 Net Revenue Details
2Q 2014 Net Revenue Details Increase Increase 2014 2013 (Decrease) 2014 2013 (Decrease) Testim revenues- Net U.S. revenues - brand $11.9 $53.2 -78% $22.8 $98.5 -77% Net U.S. revenues - AG 13.3 - N/A 13.3 - N/A International revenues 0.9 1.2 -25% 1.8 1.4 29% Total Testim revenues $26.1 $54.4 -52% $37

Slide 33: 2Q Reconciliation: GAAP to Non-GAAP Net Loss
2Q Reconciliation: GAAP to Non-GAAP Net Loss 3 Months Ended June 30, 2014 3 Months Ended June 30, 2013 GAAP Adjustments Non-GAAP GAAP Adjustments Non-GAAP Net revenues* 83.0 $ - $ 83.0 $ 100.5 $ - $ 100.5 $ Operating expenses: Cost of goods sold 30.1 (0.1) (a) 30.0 27.2 (4.5) (a) 22.7 Research and d

Slide 34: 2Q Reconciliation: GAAP to Non-GAAP Net Loss
2Q Reconciliation: GAAP to Non-GAAP Net Loss 3 Months 3 Months Ended June 30, 2014 Ended June 30, 2013 Adjustments to: (a) Costs of goods sold: Employee stock-based compensation (1) (0.1) - Acquired inventory step-up value (2) - (4.5) (0.1) $ (4.5) $ (b) Research and development: Employee stock-base

Slide 35: 1H 2014 Reconciliation: GAAP to Non-GAAP Net Loss
1H 2014 Reconciliation: GAAP to Non-GAAP Net Loss 6 Months Ended June 30, 2014 6 Months Ended June 30, 2013 GAAP Adjustments Non-GAAP GAAP Adjustments Non-GAAP Net revenues* 171.5 $ - $ 171.5 $ 166.7 $ - $ 166.7 $ Operating expenses: Cost of goods sold 48.2 (0.1) (a) 48.1 42.3 (4.6) (a) 37.7 Researc

Slide 36: 1H 2014 Reconciliation: GAAP to Non-GAAP Net Loss
1H 2014 Reconciliation: GAAP to Non-GAAP Net Loss 6 Months 6 Months Ended June 30, 2014 Ended June 30, 2013 Adjustments to: (a) Costs of goods sold: Employee stock-based compensation (1) (0.1) (0.1) Acquired inventory step-up value (2) - (4.5) (0.1) $ (4.6) $ (b) Research and development: Employee s
Source: SEC EDGAR · 425 filed Sep 10, 2014
More decks from Auxilium Pharmaceuticals Inc
Merger or Acquisition (December 2014)20 slides · Dec 3, 2014
Q3 2014 Earnings Presentation26 slides · Nov 5, 2014
Merger or Acquisition (November 2014)15 slides · Nov 5, 2014
Merger or Acquisition (October 2014)15 slides · Oct 15, 2014
Merger or Acquisition (October 2014)10 slides · Oct 10, 2014
Merger or Acquisition (October 2014)16 slides · Oct 9, 2014